Mobile

Detecting early pre-symptomatic psoriatic arthritis in patients with skin moderate or severe psoriasis - how effective is ustekinumab (Stelara) in limiting joint disease progression and future disabil...

Update Il y a 5 ans
Reference: EUCTR2012-002640-25

Detecting early pre-symptomatic psoriatic arthritis in patients with skin moderate or severe psoriasis - how effective is ustekinumab (Stelara) in limiting joint disease progression and future disability?

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

Do the imaging features of subclinical enthesopathy (the earliest change seen in psoriatic arthritis), as measured by peripheral joint ultrasound (USS) and whole body MRI, in patients with moderate-to-severe psoriasis (PASI>10), change when treated for 24 weeks with ustekinumab (at standard dose) for their psoriatic skin disease?

Inclusion criteria

  • Psoriatic disease (psoriasis and psoriatic arthritis)

Links